ebomi
Colour theme
Sign in
Insider · CIK 0001979548

Arch Venture Partners XII, LLC

CIK 0001979548 Name as filed on the most recent filing

Filed as Arch Venture Partners XII, LLC (12)

25 transaction lines · from 12 filings · filed 2023-09-20 to 2026-05-04 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-05-04 P, Open-market purchase Seaport Therapeutics, Inc.SPTX 19,800,000, acquired Open Form 4 filing 0001193125-26-204458
2025-10-27 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 4,999,977, acquired Open Form 4 filing 0001012975-25-000680
2025-08-01 P, Open-market purchase Prime Medicine, Inc.PRME 9,999,990, acquired Open Form 4 filing 0001062993-25-013461
2025-02-03 P, Open-market purchase Metsera, Inc.MTSR 2 lines 39,999,996, acquired Open Form 4 filing 0000950170-25-012579
2024-02-15 P, Open-market purchase Prime Medicine, Inc.PRME 20,000,000, acquired Open Form 4 filing 0001062993-24-003739
2023-11-14 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 40,217, acquired Open Form 4 filing 0001062993-23-020933
2023-11-13 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 371,923, acquired Open Form 4 filing 0001062993-23-020933
2023-11-10 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 2 lines 198,481, acquired Open Form 4 filing 0001062993-23-020712
2023-11-09 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 327,262, acquired Open Form 4 filing 0001062993-23-020712
2023-11-08 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 2 lines 1,017,821, acquired Open Form 4 filing 0001062993-23-020712
2023-11-07 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 347,208, acquired Open Form 4 filing 0001062993-23-020279
2023-11-06 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 497,597, acquired Open Form 4 filing 0001062993-23-020279
2023-11-03 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 255,140, acquired Open Form 4 filing 0001062993-23-020279
2023-09-29 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 483,149, acquired Open Form 4 filing 0001062993-23-018632
2023-09-28 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 2 lines 563,699, acquired Open Form 4 filing 0001062993-23-018632
2023-09-27 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 301,644, acquired Open Form 4 filing 0001062993-23-018547
2023-09-26 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 398,820, acquired Open Form 4 filing 0001062993-23-018547
2023-09-25 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 2 lines 681,464, acquired Open Form 4 filing 0001062993-23-018469
2023-09-22 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 445,600, acquired Open Form 4 filing 0001062993-23-018469
2023-09-19 P, Open-market purchase Neumora Therapeutics, Inc.NMRA 25,500,000, acquired Open Form 4 filing 0000899243-23-019274

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. ARCH Venture Partners XII, LLC, insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001979548

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.